Efficacy and safety of monoclonal antibodies against respiratory syncytial virus disease in premature infants: a systematic review and network meta-analysis.
Nirsevimab cut respiratory syncytial virus hospitalization risk most among preterm infants
Efficacy and safety of monoclonal antibodies against respiratory syncytial virus disease in premature infants: a systematic review and network meta-analysis.
Respiratory syncytial virus (respiratory syncytial virus) is a leading cause of lower respiratory tract infection (lower respiratory tract infection) in infants and young children, which may progress to bronchiolitis, pneumonia, and other severe respiratory complications.
This study aimed to evaluate the efficacy and safety of monoclonal antibodies (mAbs) against the respiratory syncytial virus disease in premature infants.
A comprehensive literature search was conducted across the PubMed, Cochrane Library, and Embase databases from inception through December 2025.
risk of hospitalization dropped sharply with nirsevimab versus placebo
This Network Meta-analysis (Network Meta-analysis) included 7 randomized controlled trials involving 4 drugs and 11319 infants.
Nirsevimab was most likely to exert the best therapeutic effects, with the highest (SUCRA) values of 94.4% for respiratory syncytial virus-related hospitalization rates and 89.1% for Intensive Care Unit admissions.
No significant differences were found in mechanical ventilation use, deaths related to respiratory syncytial virus Infections and drug-related adverse events.
Nirsevimab, motavizumab, and palivizumab all reduced respiratory syncytial virus-related hospitalizations and Intensive Care Unit admissions in preterm infants, with nirsevimab showing the greatest effect.
However, further studies are needed to confirm these findings.